Videos

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, University of Pennsylvania, discusses research into vandetanib for the treatment of patients with differentiated thyroid cancer.

Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

Jasmine Zain, MD, discusses how her institution is working on improving the outcome of patients with T cell lymphoma that undergo transplants.

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, on the use of aspirin and targeting COX-2 in colorectal cancer.

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.

Julie R. Gralow, MD, gives an overview of a phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer.

Miguel-Angel Perales, MD, from Memorial Sloan-Kettering Cancer Center, discusses the challenges regarding access to bone marrow transplant donors.

Sharon Tollin, PhD, ARNP-BC, OCN®, H. Lee Moffitt Cancer Center & Research Institute, discusses changes to the awareness of BRCA testing and breast cancer risk.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.

Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.

Mark J. Levis, MD, PhD, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.

Lawrence N. Shulman, MD, discusses molecular testing.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.

Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.

Mike Thompson, MD, PhD, from Stillwaters Cancer Support Services, discusses oncologists’ use of and attitudes towards Twitter.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.

Laura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

María-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.

Bilal Piperdi, MD, discusses the recent advancements in non-small cell lung cancer treatment and what the future might bring.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.

Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.

Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.